施乐处境艰难，向富士求救

《华尔街日报》称，随着施乐打印机和复印机业务的不断萎缩，迫于压力，施乐正在寻找新的业务增长源，并与日本相机制造商富士控股谈判，内容包括对施乐进行收购等。

由于施乐难以在办公打印机需求低迷的环境中重振其传统业务，这家总部位于康涅狄格州诺沃克的公司成为了激进投资者卡尔·伊坎的目标。与此同时，富士正努力精简其复印机业务，而将更多的精力放在了文件解决方案服务领域。

施乐是复印机行业的领军者，而富士旗下已经有一家50年历史的复印机合资企业（位于东京），专注于亚太市场，包括日本和中国，而施乐则主攻世界其他地区。

华尔街在上周三的报告中援引了来自于知情人士的消息。据其中一位人士透露，富士无意全盘收购施乐。

施乐拒绝对此置评。富士表示其不会对投机性报道置评。

施乐的市值约为77亿美元，而富士的市值约为220亿美元。

去年12月，也就是在新任命4名董事的第二天，伊坎在致股东的一封公开信中写道，由于施乐在推出新品、提升营收方面行动缓慢，因此公司“迫切”需要新的领导层。他目前持有施乐9.7%的股份，是其最大的股东。

施乐于2016年剥离了其业务流程外包部门，并拆分为两家独立上市公司。

在《华尔街日报》发布这一报道之后，富士东京股价下跌至4,724日元，跌幅1.8%，同期日本大盘的跌幅为0.3%。

复印机合资公司富士施乐成立于1962年，如今占据富士销售和运营利润的近半壁江山。

富士一直试图在其不断萎缩的照相胶卷业务之外寻找业务增长点，这也推动了公司在其他一些领域的收购动机，例如再生医药领域。

富士过去的交易包括2015年收购美国生物科技公司Cellular Dynamics International，后者是一家制造人类诱导性多能干细胞(iPS)和组织细胞的公司。

去年8月，富士表示计划在未来三年内花费5000亿日元（44.9亿美元）用于战略收购。(财富中文网)

译者：冯丰

审稿：夏林

Xerox, under pressure to find new growth sources amid shrinking demand for its printer and copier business, is in talks for a deal with Japanese camera maker Fujifilm Holdings that could include a change in control of Xerox, the Wall Street Journal reported.

Norwalk, Conn.-based Xerox been targeted by activist investor Carl Icahn as it struggles to reinvent its legacy business amid waning demand for office printing. Fujifilm is trying to streamline its copier business with a larger focus on document solutions services.

Xerox, which pioneered photocopiers, and Fujifilm already have a five-decade old Tokyo-based copier joint venture focusing on the Asia Pacific region including Japan and China, leaving Xeroxto cover the rest of the world.

The Journal report on last Wednesday cited people familiar with the matter. It also said a full takeover of Xerox is not on the table, citing one of the people.

Xerox declined to comment. Fujifilm said it would not comment on speculative reports.

Xerox has a market value of about $7.7 billion, while Fujifilm is valued at around $22 billion.

Xerox “desperately” needed new leadership as it was slow to launch new products and increase revenue, Icahn wrote in an open letter to shareholders in December, a day after nominating four members to the board. He is Xerox‘s biggest shareholder with a stake of 9.7%.

Xerox spun off its business process outsourcing unit in 2016 and separated into two independent, publicly traded companies.

Fujifilm shares fell 1.8% in Tokyo to 4,724 yen per share following the Journal report, while the broader Japanese market slipped 0.3%.

The copier joint venture, Fuji Xerox, was created in 1962 and now accounts for nearly half of Fujifilm’s sales and operating profit.

Fujifilm has been seeking growth outside its shrinking photographic film business, stepping up its acquisition drive in areas such as regenerative medicine.

Past deals include the 2015 purchase of Cellular Dynamics International, a U.S. biotechnology firm that makes human-induced pluripotent stem (iPS) cell lines and tissue cells.

Last August, it said it aimed to spend 500 billion yen ($4.49 billion) in strategic acquisitions over three years.